Medtech

3 Boomerang Capital I, L.P. is a healthcare-focused private equity fund targeting the lower middle market, managed by 3 Boomerang Capital (3BC), a Greenwich, Connecticut–based firm founded in 2023 by Adam Dolder and Adam Elberg. Both founders bring prior careers as both healthcare investors and healthcare entrepreneurs — a dual background the firm describes as fundamental to its differentiated approach. 3BC focuses exclusively on founder-led businesses in the healthcare sector, providing not only capital but operational guidance drawn from firsthand experience scaling and managing healthcare enterprises. The firm operates with an eleven-person team structured to provide hands-on engagement with portfolio companies. 3 Boomerang Capital I targets four sub-sectors within healthcare: BioPharma outsourcing (contract research, manufacturing, and laboratory services), medical device and diagnostic manufacturing, information technology and tech-enabled services for healthcare, and alternate site care (outpatient, home health, and specialty clinic settings). The fund targets lower middle market businesses — typically generating $10M–$100M in revenue — where management depth, succession planning, and operational systems can benefit from private equity partnership. Geographic focus spans North America and select Western European markets with established healthcare infrastructure. Fund I surpassed its $350 million target, closing above $375 million of total commitments from a diversified LP base including leading endowments, foundations, pension funds, insurance companies, fund-of-funds, and family offices, in addition to 3BC professionals. The final close was announced on February 6, 2024. Initial portfolio activity includes a growth recapitalization of Professional Physical Therapy (ProPT), described as the largest outpatient physical therapy business in the Northeastern United States. The successful above-target close on its inaugural fund validates the founding team's thesis that founder-aligned, healthcare-specialist private equity is a durable and differentiated strategy in the lower middle market.

AAIC Africa Healthcare Fund (AHF No. 1) is a $47 million impact-oriented venture capital fund focused exclusively on healthcare and medical technology startups across sub-Saharan Africa and North Africa, managed by AAIC Investment Pte. Ltd. (Asia Africa Investment & Consulting), headquartered in Singapore. AHF1 was established in 2017 as the first Japanese-affiliated venture capital fund to operate from Kenya, marking a landmark in Japanese private capital engagement with the African startup ecosystem. The fund was inspired by an assessment of the acute shortage of healthcare infrastructure across Africa and the concurrent emergence of mobile-first health technology startups capable of leapfrogging traditional delivery systems. The advisory committee includes Mr. Yoshiyuki Sato, with 50 years of Africa business experience, and Dr. Amit N. Thakker, Chairman of the Africa Healthcare Federation. AHF1 deploys tickets between $100,000 and $5 million per company, targeting seed through Series B stages across four primary African markets: Kenya, Nigeria, South Africa, and Egypt — countries representing the largest and most developed startup ecosystems on the continent. The investment mandate covers the full healthcare stack: primary care and hospital services, diagnostics, digital health and telemedicine, pharmaceutical distribution, medical devices, and healthcare-adjacent fintech applications including healthcare payment infrastructure. AAIC operates from offices in Nairobi, Lagos, and Johannesburg, enabling close portfolio engagement and deal sourcing across the region. AHF1 invested in 30 companies over its deployment cycle and has produced notable portfolio outcomes. Chipper Cash, a fintech-adjacent portfolio company, achieved unicorn status in 2021 following its $250 million Series C funding round led by Decacorn Capital. The fund's success catalyzed AAIC's expansion into a second vehicle, the Africa Innovation and Healthcare Fund (AHF2), which broadened the mandate beyond healthcare to include broader innovation sectors. AHF1 remains a pioneering example of Japanese institutional capital accessing the African venture ecosystem through a specialized healthcare and impact-aligned strategy.

The Africa Innovation and Healthcare Fund 1 (AHF-1) is a venture capital and impact fund managed by AAIC Investment, a Japan-based investment manager dedicated to advancing healthcare and innovation across the African continent. Launched in 2017 as Japan's first fund with an exclusive focus on the African healthcare sector, AHF-1 represents a pioneering effort to channel institutional capital from Japanese financial institutions and corporations into high-growth, mission-driven businesses across Sub-Saharan Africa. AHF-1 targets early- to late-stage companies operating across the full spectrum of healthcare and adjacent verticals, including clinical care, medical services, digital health, health technology, pharmaceutical distribution, insurance, diagnostics, and health-enabling infrastructure such as fintech and mobility. The fund takes equity positions and provides hands-on operational and strategic support to portfolio companies through AAIC's deep local networks in Kenya, Nigeria, Egypt, Rwanda, and other key African markets. The investment thesis centers on the belief that healthcare companies in Africa can achieve strong financial returns while addressing acute social challenges in underserved markets. AHF-1 reached a final close at USD 47 million and deployed capital across more than 30 startups and established companies, establishing AAIC Investment as one of the leading Japan-Africa impact investors in the private markets space. The fund's success laid the foundation for the Africa Innovation and Healthcare Fund 2 (AHF-2), launched in 2022 with a USD 150 million target, continuing to scale the manager's pan-African healthcare investment franchise. AAIC Holdings Pte. Ltd., headquartered in Singapore, serves as the parent organization with regional operations across Africa and Asia.

Atlas Venture Fund XIV is a US$450 million early-stage venture capital fund launched by Atlas Venture, one of the leading life sciences VC firms based in Cambridge, Massachusetts. The fund completed its final close in December 2024 after an oversubscribed fundraising process that general partner Bruce Booth described as 'the smoothest, most efficient, and most oversubscribed fundraise' in the firm's 20-year history of biotech investing — noting the fund could have been raised at several multiples of its target. Fund XIV is led by general partners Kevin Bitterman, Bruce Booth, Michael Gladstone, David Grayzel, and Jason Rhodes, and was backed by a 'marquee group of long-term institutional investors.' The fund maintains an identical size to its predecessor, Fund XIII (US$450 million, closed February 2022), a deliberate choice rooted in the firm's capital discipline philosophy. Atlas Venture employs a distinctive 'seed-led venture creation model,' where the firm actively co-creates most portfolio companies rather than accepting unsolicited pitches. The partnership builds biotech companies based on scientific discoveries and technologies, typically securing 50-70% initial ownership stakes before dilution through subsequent financing rounds. Fund XIV targets seed and Series A investments in early-stage biotech companies across disease areas, treatment modalities, and business models, with a typical portfolio construction of 20-25 deals per vintage. The fund's capital-constrained approach reflects what Booth has termed the 'VC Math Problem' — larger funds face mathematical constraints in delivering targeted 3x+ net returns given realistic exit value distributions and ownership percentages at later stages. Atlas Venture manages approximately US$3 billion in total assets across all funds and has operated from a single Cambridge, Massachusetts office since its founding. Fund XIII demonstrated strong early performance with portfolio exits including the acquisition of the Nimbus Tyk2 program, Versanis Bio, Aiolos Bio, and Mariana Oncology, while also launching 16 new biotech businesses since 2022. The broader Atlas portfolio currently includes approximately 50 active clinical trials, reflecting deep scientific engagement across portfolio companies. Fund XIV's close came immediately before Atlas's September 2025 announcement of Opportunity Fund III (US$400 million), the two funds together constituting Atlas's dual-fund model for early-stage creation and later-stage follow-on capital.

Columbus Innvierte Life Science I is the debut venture capital fund managed by Columbus Venture Partners, a Valencia, Spain-based life sciences investor founded in 2016 by Javier García and Damià Tormo. The fund was registered with the Spanish securities regulator CNMV (registration no. 190) and launched in April 2016 as part of Spain's Innvierte programme, a public-private co-investment initiative supporting early-stage innovation. The fund raised EUR 42 million and had an investment period running from 2016 to 2018, making seed and Series A investments in deep biotech and advanced therapy companies, primarily in Spain. The fund's strategy combined scientific expertise in therapeutic development with an industrial vision, targeting companies working on cell and gene therapies, AAV vector manufacturing, and other disruptive life sciences platforms. Columbus Venture Partners brought a distinctive approach of investing in both product development and the manufacturing infrastructure required to scale these technologies, thereby shortening time to exit. The geographic focus was Spain with international reach, co-investing alongside specialist international and corporate venture funds. The fund built a portfolio of eight investments and has since generated exceptional returns through landmark exits. Viralgen Vector Core was sold to Bayer in 2020 in a transaction valued at approximately EUR 4 billion. Vivet Therapeutics was acquired by Pfizer for an upfront and option value of EUR 560 million. Aura Biosciences completed a NASDAQ IPO in 2021. Columbus Venture Partners now manages over EUR 400 million across four successive funds, establishing itself as one of Spain's leading life sciences venture capital franchises.

Deerfield Healthcare Innovations Fund III is the third installment in Deerfield Management's series of venture capital funds dedicated to advancing healthcare. Launched in May 2025, the fund has secured over $600 million in commitments, aiming to invest in promising therapeutics, improvements to healthcare delivery, and paradigm-shifting technologies, including machine learning and artificial intelligence. The fund's strategy leverages Deerfield's collaborations with 29 leading research institutions and nine industry partners. Through its in-house ecosystem, including specialized teams like Deerfield Discovery and Development (3DC) and Deerfield Intelligence, the firm identifies and advances innovative products, services, and technologies. These efforts are often in partnership with Deerfield-founded entities such as Deerfield Catalyst and Genscience. Operating from its twelve-story healthcare innovation campus, Cure, in New York City, Deerfield provides state-of-the-art research laboratories and convening spaces to support health innovators. Consistent with its long-standing practice, a portion of the profits from Healthcare Innovations Fund III not allocated to the fund's limited partners will be donated to the Deerfield Foundation, a not-for-profit organization focused on improving the health of children worldwide.

The fund is the fourth flagship vehicle from GHO Capital, leveraging its deep specialization in healthcare to back companies delivering better, faster and more accessible care. With its final close at over €2.5 billion, the vehicle is positioned to scale high‑growth businesses across services, medtech, diagnostics and health‑tech platforms. GHO Capital IV focuses on companies where strong management, operational improvement and international expansion can unlock significant value. The fund partners with leadership teams in niche but growing healthcare subsectors and applies the firm’s sector insight, global network and operational resources to drive transformation. The strategy targets enterprises that serve pharmaceutical, biotechnology and medical device customers — such as CDMOs, contract services, outsourcing platforms, diagnostics manufacturers and digital health enablers — where structural tailwinds and under‑penetrated markets offer runway for growth. Geographically, the fund emphasises Europe and North America but retains flexibility to leverage cross‑border dynamics, enabling portfolio companies to scale internationally. Through disciplined buy‑outs, add‑on consolidation and operational acceleration, GHO Capital IV aims to d

Mérieux Innovation 2 (MI2) is the second-generation venture capital fund managed by Mérieux Equity Partners, focused on advancing innovation in the healthcare sector. Building on the success of its predecessor, MI2 is designed to support early-stage companies with high-impact solutions across diagnostics, medical devices, and pharmaceutical services. The fund targets platform-based business models with validated proof of concept, offering scalability and long-term growth potential. MI2 combines capital investment with strategic guidance and access to a robust healthcare ecosystem, helping portfolio companies accelerate development and go-to-market strategies. MI2 has received the prestigious Tibi label, highlighting its commitment to driving technological innovation within France and the broader European healthcare landscape. It aims to generate strong returns while contributing meaningfully to patient care and clinical outcomes. The fund’s first investment is a €6 million commitment to DeepUll, a Spanish diagnostics company developing rapid sepsis detection technology. This aligns with MI2’s goal of supporting transformative platforms that address critical medical needs.